Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 29, 2014 17:01 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference

CAMBRIDGE, Mass., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
January 28, 2014 08:00 ET | Source: Idenix Pharmaceuticals

Idenix to Raise $106.7 Million Through Registered Direct Offering

CAMBRIDGE, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
January 13, 2014 07:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir

CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
January 07, 2014 08:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 32nd Annual J.P. Morgan...
January 06, 2014 08:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
December 09, 2013 08:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Announces Declaration of Senior Party in a Second Patent Interference by the USPTO

CAMBRIDGE, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
December 02, 2013 07:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection

CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
December 02, 2013 07:00 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences

CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
November 25, 2013 16:05 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences

CAMBRIDGE, Mass., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a fireside chat discussion at the 2013...
October 30, 2013 16:05 ET | Source: Idenix Pharmaceuticals

Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2013 Financial Results and Provides HCV Pipeline Update

-- Enrollment initiated for a phase I/II clinical trial for IDX21437, a next-generation uridine nucleotide prodrug inhibitor for the treatment of hepatitis C virus infection (HCV) -- Initiation...